207 related articles for article (PubMed ID: 24354854)
1. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.
Ha H; Bensman T; Ho H; Beringer PM; Neamati N
Br J Pharmacol; 2014 Mar; 171(6):1551-65. PubMed ID: 24354854
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
Kaur M; Singh D
J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
[TBL] [Abstract][Full Text] [Related]
3. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions.
Raghuwanshi SK; Su Y; Singh V; Haynes K; Richmond A; Richardson RM
J Immunol; 2012 Sep; 189(6):2824-32. PubMed ID: 22869904
[TBL] [Abstract][Full Text] [Related]
5. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.
Nasser MW; Raghuwanshi SK; Grant DJ; Jala VR; Rajarathnam K; Richardson RM
J Immunol; 2009 Sep; 183(5):3425-32. PubMed ID: 19667085
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.
Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616
[TBL] [Abstract][Full Text] [Related]
7. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.
White JR; Lee JM; Young PR; Hertzberg RP; Jurewicz AJ; Chaikin MA; Widdowson K; Foley JJ; Martin LD; Griswold DE; Sarau HM
J Biol Chem; 1998 Apr; 273(17):10095-8. PubMed ID: 9553055
[TBL] [Abstract][Full Text] [Related]
8. Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models.
Su Y; Raghuwanshi SK; Yu Y; Nanney LB; Richardson RM; Richmond A
J Immunol; 2005 Oct; 175(8):5396-402. PubMed ID: 16210646
[TBL] [Abstract][Full Text] [Related]
9. Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.
Richardson RM; Marjoram RJ; Barak LS; Snyderman R
J Immunol; 2003 Mar; 170(6):2904-11. PubMed ID: 12626541
[TBL] [Abstract][Full Text] [Related]
10. Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis.
Lane HC; Anand AR; Ganju RK
Int Immunol; 2006 Aug; 18(8):1315-25. PubMed ID: 16798838
[TBL] [Abstract][Full Text] [Related]
11. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of Distinct Roles of Guinea Pig CXCR1 and CXCR2 in Neutrophil Migration toward IL-8 and GROα by Specific Antibodies.
Tanaka K; Yoshitomi T; Hirahara K
Biol Pharm Bull; 2017; 40(5):729-732. PubMed ID: 28458362
[TBL] [Abstract][Full Text] [Related]
13. GRPR antagonist protects from drug-induced liver injury by impairing neutrophil chemotaxis and motility.
Czepielewski RS; Jaeger N; Marques PE; Antunes MM; Rigo MM; Alvarenga DM; Pereira RV; da Silva RD; Lopes TG; da Silva VD; Porto BN; Menezes GB; Bonorino C
Eur J Immunol; 2017 Apr; 47(4):646-657. PubMed ID: 28294319
[TBL] [Abstract][Full Text] [Related]
14. Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization.
Boon K; Vanalken N; Szpakowska M; Chevigné A; Schols D; Van Loy T
Cell Commun Signal; 2024 Jan; 22(1):43. PubMed ID: 38233929
[TBL] [Abstract][Full Text] [Related]
15. Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.
Vacchini A; Mortier A; Proost P; Locati M; Metzemaekers M; Borroni EM
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486423
[TBL] [Abstract][Full Text] [Related]
16. N-acetylated Proline-Glycine-Proline induced G-protein dependent chemotaxis of neutrophils is independent of CXCL8 release.
Overbeek SA; Henricks PA; Srienc AI; Koelink PJ; de Kruijf P; Lim HD; Smit MJ; Zaman GJ; Garssen J; Nijkamp FP; Kraneveld AD; Folkerts G
Eur J Pharmacol; 2011 Oct; 668(3):428-34. PubMed ID: 21458443
[TBL] [Abstract][Full Text] [Related]
17. LIM and SH3 protein-1 modulates CXCR2-mediated cell migration.
Raman D; Sai J; Neel NF; Chew CS; Richmond A
PLoS One; 2010 Apr; 5(4):e10050. PubMed ID: 20419088
[TBL] [Abstract][Full Text] [Related]
18. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection.
Tarzami ST; Miao W; Mani K; Lopez L; Factor SM; Berman JW; Kitsis RN
Circulation; 2003 Nov; 108(19):2387-92. PubMed ID: 14568904
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
Casilli F; Bianchini A; Gloaguen I; Biordi L; Alesse E; Festuccia C; Cavalieri B; Strippoli R; Cervellera MN; Di Bitondo R; Ferretti E; Mainiero F; Bizzarri C; Colotta F; Bertini R
Biochem Pharmacol; 2005 Feb; 69(3):385-94. PubMed ID: 15652230
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
